NASDAQ: EQ - Equillium, Inc.

Yield per half year: -51.27%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Equillium, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Equillium, Inc.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis.

more details
It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2018-10-11
ISIN US29446K1060
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://equilliumbio.com
Цена ао 0.758
Change price per day: -16.93% (0.488)
Change price per week: -47.55% (0.773)
Change price per month: -47.01% (0.765)
Change price per 3 month: -41.59% (0.694)
Change price per half year: -51.27% (0.832)
Change price per year: -82.45% (2.31)
Change price per 3 year: -87.68% (3.29)
Change price per 5 year: -92.05% (5.1)
Change price per year to date: -38.58% (0.66)
All parameters

Underestimation

Title Value Grade
P/S 0.6101 10
P/BV 0.9753 9
P/E 0 0
EV/EBITDA 0.0261 10
Total: 6.13

Efficiency

Title Value Grade
ROA, % -26.39 0
ROE, % -59.08 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0572 10
Total: 9

Growth impulse

Title Value Grade
Yield Revenue, % 128.97 10
Yield Ebitda, % -54.54 0
Yield EPS, % -73.88 0
Total: 2
More

Institutions Volume Share, %
Decheng Capital Management III (Cayman), LLC 4447308 12.61
Decheng Capital LLC 4447308 12.61
Vanguard Group Inc 836930 2.37
Cota Capital Management, LLC 562278 1.59
Tang Capital Management, LLC 400000 1.13
JP Morgan Chase & Company 350031 0.99
Renaissance Technologies, LLC 347500 0.99
Geode Capital Management, LLC 172387 0.49
Commonwealth Equity Services, LLC 100000 0.28
Callan Capital LLC 99688 0.28



Head Job title Payment Year of birth
Mr. Daniel Mark Bradbury Executive Chairman 158k 1961 (64 years)
Mr. Bruce D. Steel C.F.A. Co-Founder, President, CEO & Director 779.87k 1966 (59 years)
Ms. Christine Zedelmayer M.B.A., P.M.P. Senior VP & COO 553.73k 1970 (55 years)
Dr. Stephen Connelly Ph.D. Chief Scientific Officer & Director 571.32k 1982 (43 years)
Mr. Jason A. Keyes Chief Financial Officer N/A 1971 (54 years)
Mr. Michael Moore Vice President of Investor Relations & Corporate Communications N/A
Dr. Matthew Ritter Ph.D. Senior Vice President of Corporate Development N/A
Mr. Joel M. Rothman Chief Development Officer N/A 1969 (56 years)
Penny Tom Senior VP of Finance & Principal Accounting Officer N/A

Address: United States, La Jolla. CA, 2223 Avenida De La Playa - open in Google maps, open in Yandex maps
Website: https://equilliumbio.com